16:39 EST Outlook Therapeutics (OTLK) files to sell 7.07M shares of common stock for holders
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics re-submits BLA to U.S. FDA for ONS-5010
- Outlook Therapeutics price target lowered to $10 from $12 at Guggenheim
- Positive Outlook on Outlook Therapeutics: Buy Rating Supported by Strategic Launches and Market Opportunities for Lytenava
- Outlook Therapeutics price target lowered to $3 from $30 at H.C. Wainwright
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?